

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

SUIT-2

RRID:CVCL_3172

Type: Cell Line

Proper Citation

RRID:CVCL_3172

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3172

Proper Citation: RRID:CVCL_3172

Description: Cell line SUIT-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: [PMID:1391733](#), [PMID:3102439](#), [PMID:11169959](#), [PMID:11787853](#), [PMID:11854916](#), [PMID:12800145](#), [PMID:19077451](#), [PMID:20215515](#), [PMID:21607521](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SUIT-2

Synonyms: Suit-2, SUIT 2, SUIT2, Suit2, SUIzo Tumor-2

Cross References: BTO:BTO_0003493, CLO:CLO_0037114, EFO:EFO_0006495, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:365, BioSample:SAMN03472902, BioSample:SAMN10988018, cancercellines:CVCL_3172, Cell_Model_Passport:SIDM00371, Cosmic:710872, Cosmic:755300, Cosmic:808161, Cosmic:918051, Cosmic:1108340, Cosmic:1320464, Cosmic:1534322, Cosmic:1995647, Cosmic:2664046, Cosmic-CLP:1240219,

DepMap:ACH-000652, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10797-110I5, GDSC:1240219, GEO:GSM244426, GEO:GSM244427, GEO:GSM827218, GEO:GSM887657, GEO:GSM888749, GEO:GSM1588615, GEO:GSM1588627, GEO:GSM1670489, IARC_TP53:16745, JCRB:JCRB1094, LiGeA:CCLE_481, LINCS_LDP:LCL-1729, Lonza:1079, PharmacDB:SUIT2_1507_2019, PRIDE:PXD030304, Progenetix:CVCL_3172, TKG:TKG 0705, Wikidata:Q54970817

ID: CVCL_3172

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260815T235920+0000

Ratings and Alerts

No rating or validation information has been found for SUIT-2.

No alerts have been found for SUIT-2.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ma B, et al. (2026) MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer. Molecular cancer research : MCR.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Cell reports, 45(5), 117314.

Gong D, et al. (2025) Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. Science advances, 11(42), eadx0632.

Nishikubo K, et al. (2025) Sustained reductions in valine and isoleucine mediate anti-cancer pharmacological effects of inhibiting amino acid transporter LAT1 in cancer cells. Cancer & metabolism, 13(1), 46.

Khine HEE, et al. (2025) Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways. Scientific reports, 15(1), 11376.

Campos AD, et al. (2025) A STAT3/integrin axis accelerates pancreatic cancer initiation and progression. Cell reports, 44(8), 116010.

Dobersch S, et al. (2025) HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. *Nature communications*, 16(1), 4866.

Cunniff PJ, et al. (2025) KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. *Nature communications*, 16(1), 9996.

Ishihara S, et al. (2025) Stiff extracellular matrix activates the transcription factor ATF5 to promote the proliferation of cancer cells. *iScience*, 28(3), 112057.

Alruwaili MM, et al. (2024) A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers. *Cell reports. Medicine*, 5(3), 101434.

Zhang S, et al. (2024) Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. *Cell death discovery*, 10(1), 124.

Shrestha H, et al. (2024) The Janus kinase 1 is critical for pancreatic cancer initiation and progression. *Cell reports*, 43(5), 114202.

Dcona MM, et al. (2023) Combined Targeting of NAD Biosynthesis and the NAD-dependent Transcription Factor C-terminal Binding Protein as a Promising Novel Therapy for Pancreatic Cancer. *Cancer research communications*, 3(10), 2003.

Zhang J, et al. (2023) Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. *Cancers*, 15(19).

Vall??s-Mart?? A, et al. (2023) Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. *Cell reports*, 42(6), 112581.

Yoon SJ, et al. (2023) Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. *Cancer research*, 83(9), 1426.

Kuroda Y, et al. (2023) Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN lectin. *Cancer science*, 114(8), 3364.

Zeng S, et al. (2022) CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. *Journal of experimental & clinical cancer research : CR*, 41(1), 241.

Abt ER, et al. (2022) Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. *Cell reports*, 38(2), 110236.

He H, et al. (2022) Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator. *Cancers*, 15(1).